Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2001, Pages 429-440

  Smaill, J B ^a   Hollis Showalter, H D ^b   Zhou, H ^b   Bridges, A J ^b   McNamara, D J ^b   Fry, D W ^b   Nelson, J M ^b   Sherwood, V ^b   Vincent, P W ^b   Roberts, B J ^b   Elliott, W L ^b   Denny, W A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANILINOPYRIDO[3,4 D]PYRIMIDINE DERIVATIVE; 4 ANILINOQUINAZOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; N [4 (3 BROMOANILINO)PYRIDO[3,4 D]PYRIMIDIN 6 YL] N METHYLACRYLAMIDE; N1 [4 (3 CHLORO 4 FLUOROANILINO)PYRIDO[3,4 D]PYRIMIDIN 6 YL] N4 [3 (4 MORPHOLINYL)PROPYL] 2 BUTENEDIAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; DRUG MECHANISM; DRUG OXIDATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MICE; PHOSPHORYLATION; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035253847     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000372i     Document Type: Article

References (24)

1. Assessment of HER2 status in breast cancer: Why, when and how?
2. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
3. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
4. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones
5. The epidermal growth factor receptor and its inhibition in cancer therapy
6. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazinoquinazolines as EGFR inhibitors: Synthesis, biological evaluation and modelling of the mode of binding
7. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
8. Inhibition of epidermal growth factor receptor-associatod tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
9. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
10. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
11. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
12. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-378,785)
13. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
14. Tyrosine kinase inhibitors. 15.4-(phenyl-amino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
15. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
16. Investigation of the effects of the tyrosine kinase (TK) inhibitor CI-1033 (PD 0183805) against human tumor specimens taken directly from patients
17. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]-pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
18. 5-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor
19. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
20. Rapid syntheses of some indole alkaloids of the Calabar bean
21. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]-pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor
22. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors
23. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice
24. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato-(2-)](2-methyl-1,4-butanediamine-N ,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo